Target market expansion following full approval in the US
JANUARY -
- Net sales amounted to
SEK 295.5 million , of which TARPEYO® net sales amounted toSEK 278.3 million , for the three months endedMarch 31, 2024 . For the three months endedMarch 31, 2023 , net sales amounted toSEK 191.4 million , of which TARPEYO net sales amounted toSEK 185.7 million . -
Operating loss amounted to
SEK 203.8 million andSEK 180.1 million for the three months endedMarch 31, 2024 , and 2023, respectively. -
Loss per share before and after dilution amounted to
SEK 4.59 andSEK 3.49 for the three months endedMarch 31, 2024 , and 2023, respectively. -
Cash amounted to
SEK 810.3 million andSEK 1,013.6 million as ofMarch 31, 2024 , and 2023, respectively.
"In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2." - CEO
KEY TAKEAWAYS FROM Q1, 2024
|
KEY EVENTS AFTER THE REPORTING PERIOD
|
Outlook for 2024: Unchanged
Calliditas expects continued revenue growth:
Total net sales from the Nefecon franchise, including milestones, are estimated to be
Investor Presentation:
Link to webcast:
To participate via conference call register via this link: Call Access (financialhearings.com)
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information in the report is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on
About Calliditas
Forward-Looking Statements
This Interim Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas' strategy, business plans, revenue and other financial projections, and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this Interim Report are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Interim Report, including, without limitation, any related to Calliditas' business, operations, commercialization of TARPEYO, Kinpeygo and Nefecon, clinical trials, supply chain, strategy, goals and anticipated timelines for development and potential approvals, competition from other biopharmaceutical companies, revenue and product sales projections or forecasts, including 2024 total net sales guidance and cash runway and preliminary net sales for the second quarter of 2024 to date, and other risks identified in the section entitled "Risk Factors" in Calliditas' reports filed with the
Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this Interim Report represent Calliditas' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
https://news.cision.com/calliditas-therapeutics/r/calliditas-q1-report--january---march-2024,c3986496
https://mb.cision.com/Main/16574/3986496/2816066.pdf
https://mb.cision.com/Public/16574/3986496/8e28fb584e477801.pdf
(c) 2024 Cision. All rights reserved., source